International leprosy Congress Beijing 2016: Programme of Scientific Sessions (8 August)

- There are 49 parallel sessions and workshops in the Scientific Programme.
- The structure of the programme attempts to avoid time clashes of topic and presenter.
- Each presentation is 10 minutes (maximum of 10 slides) plus 5 minutes discussion.
- Strict time keeping by chairs and presenters is essential with 270 papers.

Session 1. Drug resistance 1 (in collaboration with ESCMID/ESGMYC)  Chair: Cambau

**Monday 19th September 13.30 hours**  Room 201AB

- **ILC1.2-025 1.1** Surveillance of drug resistance in M. leprae  Emmanuelle Cambau
- **ILC5.2-039 1.2** Inclusion of Surveillance after RFT into Routine Leprosy Control Activity using “BOK”: lesson learnt from Gorontalo, Indonesia  DiahFita Sari
- **ILC1.2-024 1.3** Genome downsizing and drug resistance in Mycobacterium leprae: are there places for drug efflux pumps?  Miguel Viveiros
- **ILC4.4-009 1.4** Surveillance of resistant M. leprae strains at Lauro de Souza Lima Institute, Bauru-SP, Brazil Patricia Rosa
- **ILC1.2-009 1.5** Molecular Investigation and Characterization of Phenotypically Rifampicin-Resistant Mycobacterium leprae Samples Lacking Known rpoB Resistance Mutations  Deanna A. Hagge

Session 2.  Panel: clinical Problems in Leprosy  Chair: Naafs

**Monday 19th September 13.30 hours**  Room 201CD

Clinical questions requested

Session 3.  French Session 1  Chair: Tiendrebeogo

**Monday 19th September 13.30 hours**  Room 203ABCD

- **ILC2.4-026 3.1** stratégie de dépistage de lépreen zone endémiquefortementislamisé et en zone de rébellionindépendantisteoù la maladieavaitétédéclaréeéradiquée depuis 10 ans?  Mahamath Cissé
- **ILC4.2-034 3.2** Etude sur l’accès aux soins de santé chez les maladeslépreux au Burundi  Michel Sawadogo
- **ILC4.2-045 3.3** Maintien de l’expertiselèpre au niveau des acteurs du système de santé :Expérience de la c?te d’ivoire  RigobertAbbetAbbet
- **ILC4.2-047 3.4** Uneexpériencexpilote de consultation avancée de dermatologie pour améliorer la détection des cas de Lèpre à Madagascar.  Bertrand Cauchoix
- **ILC4.2-048 3.5** Mise en ?uvrepilote au Tchadd’unestratégie de dépistageavancé de la Lèpre sur des districts ciblés  Bertrand Cauchoix
Session 4. Human rights

Monday 19th September 13.30 hours

ILC2.2-001 4.1 Nagashima Aisei-en and the Legacy of Human Rights: A Partnership to Teach the Lessons of Hansen’s Disease in Japan  "Kathryn Tanaka, Tomohisa Tamura, John Jackson, and Koji Ozaki

ILC2.2-003 4.2 Commitment to influence change  Kilyong Lee

ILC2.2-007 4.3 The evaluation of Integrating Prasart leprosy colony into general community, Surin Province, Thailand  Gomes Unarat

ILC2.2-002 4.4 Writing Life: Illness, Isolation, and the Importance of HōjōTamio’s Fiction  Kathryn Tanaka

ILC2.2-008 4.5 Experiencing stigma and discrimination and the inspiration of gaining back human dignity: Life story of people affected by leprosy, Khonkaen province, Thailand  Parkit Gijawat

ILC2.2-015 4.6 Enhanced Participation in Society Through Involvement in National Human Rights Organization Representing Persons With Disabilities  Shehu Sarkin Fada

Session 5. Global Strategies

Monday 19th September 13.30 hours

ILC4.2-070 5.1 May be WHO elimination target hiding patients instead of eliminating leprosy? A case in Pará State, Brazilian Amazon  Claudio Guedes Salgado

ILC4.2-096 5.2 The health economic evaluation of the leprosy suspicious cases and monitoring system in Zhejiang  Li-juan FEI

ILC4.2-098 5.3 A long way to wipe out leprosy thoroughly with great responsibility  zhongshengzeng

ILC4.2-038 5.4 Global elimination of leprosy by 2020: are we on track?  David Blok

ILC4.2-011 5.5 Cost Effectiveness of Leprosy Control Program Models in Thailand  Kulprapat Pairayayutakul

Session 6. Early detection and transmission research (LRI)

Monday 19th September 13.30 hours

ILC4.4-027 6.1 Early Detection and Transmission Workshop  Thomas P. Gillis

ILC1.2-007 6.2 A Molecular Assay for Determining Mycobacterium leprae Viability in Tissues and its Application to Clinical Samples  Linda Adams
ILC4.3-010  6.3  Field Evaluation of Novel Immunodiagnostic Tools for Early Detection of Leprosy in BCG Vaccination Field Trial amongst Contacts of Leprosy Patients  Jan Hendrik Richardus

ILC2.3-017  6.4  A participatory, translational, social science pilot study to inform earlier detection and reduced transmission  Pim Kuipers

ILC4.2-046  6.5  A comparison of three types of targeted, community-based health education aimed at promoting early detection  Annamma John

Session 7.  Social Aspects 1  Chair: Michael Chen/J Ramirez

Monday 19th September 13.30 hours  Room 307

ILC2.3-018  7.1  From an uneducated boy to a chief prosthesis technician - A Case Study of Participation and Empowerment  Michael Zhiqiang Chen

ILC2.3-045  7.2  The Leprosy Mission Nepal’s Disaster Response: Capacity Building at Community Level  Rakchhya Maharjan

ILC2.3-019  7.3  From isolation to social integration — the impact of empowerment in leprosy rehabilitation service  Michael Zhiqiang Chen

ILC2.3-050  7.4  Socio economic profile and empowerment status of leprosy colony dwellers  Sam Philip

ILC2.3-020  7.5  Social Enterprise - A Way of Social Integration  Michael Zhiqiang Chen

ILC2.3-061  7.6  A Counselor’s Notes along the Journey with the leprosy affected. Valsa Augustine

Session 8.  Health Systems  Chair: Shahed Hossain/J Kawuma

Monday 19th September 13.30 hours  Room 308

ILC4.2-017  8.1  Integration of Leprosy Services into General Care in Bangladesh: Approaches and Tools to Facilitate Changes  Shahed Hossain

ILC4.2-018  8.2  Leprosy new case detection trends and the future effect of preventive interventions in Pará State, Brazil: a modelling study  Haroldo Matos

ILC4.2-025  8.3  Accuracy of the Leprosy Alert Response Network and Surveillance (LEARNS) System of the Novartis Foundation and Philippine Department of Health - National Leprosy Control Program  John Q. Wong

ILC4.2-044  8.4  The development of communication model in commercial area along Thai-Cambodian borders  Niyom Kraipui

ILC4.2-052  8.5  Cambodia Retrospective Active Case Finding project: recommendations for targeting high-priority districts in phase 2  Peter Steinmann

ILC4.2-112  8.6  The capacity of case finding before and after cancelation or merging of Some Professional Leprosy-control Institution in Hunan Province  Minghua HUANG
Session 49  Mapping and Geographical Analysis  Chair: Paul Saunderson
Monday 19th September 13.30 hours  Room 311
ILC4.5-004  16.1  Mapping cases and morbidity for diseases such as leprosy and Buruli ulcer: a new approach  Paul Saunderson
ILC4.2-055  16.2  LEPROSY MAPPING IN ETHIOPIA  Maria Saba Lambert
ILC4.1-021  16.3  The distribution of district-level leprosy incidence in India is geometric-stable, consistent with subcriticality  Travis Porco
ILC4.1-011  16.4  Spatial Distribution of Leprosy in Bangladesh: Tool to Assess the Trends and Programmatic Implications  Shahed Hossain
ILC4.2-006  16.5  The Important Role of Mobile Phone in Monitoring Leprosy Cases in Cebu, Philippines  Marivic Balagon
ILC4.1-018  16.6  Android based software for field data collection in Leprosy; effectiveness and advantages of the tool as an integral part of epidemiological survey  Pankaj Thomas

Session 9.  Best Practice  Chair: Lehman
Monday 19th September 15.30 hours  Room 201AB
ILC1.1-054  9.1  What has happened 24 years after the development and adaptation of using Semmes-Weinstein Monofilaments in Brazil’s national Hansen’s disease (leprosy) control activities?  Linda Faye Lehman
ILC1.1-057  9.2  Field testing of a common skin diseases approach to detect leprosy, other NTDs and HIV-related skin diseases in Mozambique: a health systems strengthening approach using a smartphone app.  Erik Post
ILC1.1-061  9.3  Leprosy in Children: A 20 year retrospective case review in Nepal  Ruby Thapa
ILC1.1-022  9.4  Mobile Clinic Initiative At Leprosy Settlement In Lagos State In South West Nigeria; A Proactive Approach To Disability Prevention And Ulcer Care  Osman Eltayeb
ILC1.1-033  9.5  MOBILEP: A Special Initiative to Improve Digital Data collection in Leprosy through Mobile Phone  David Pahan
ILC1.1-050  9.6  Challenges of thalidomide control in Brazil  Isabella Pinto
ILC1.1-051  9.7  Early Diagnosis of leprosy based on Multiple Assays  Yan Wen

Session 10.  ENL Workshop  Chair: Walker
Monday 19th September 15.30 hours  Room 201CD
ILC1.3-024  10.1  ENL Reactions Workshop: Erythema Nodosum Leprosum  Stephen Walker
ILC3.1-040  10.2  Genetic and Non genetic factors associated with inflammatory reactions in leprosy
            Caroline De Sales-Marques/Milton Ozorio Moraes

ILC1.3-011  10.3  The Erythema Nodosum Leprosum International Study Group – a progress report
            Stephen Walker

ILC1.3-026  10.4  The Impact of Erythema Nodosum Leprosum on Health Related Quality of Life in Surabaya, Indonesia – an ENLIST Group Study
            Denisa Alinda Medhi

ILC1.3-013  10.5  The Development of a Severity Scale for Erythema Nodosum Leprosum – the ENLIST ENL Severity Scale
            Stephen Walker

ILC1.3-012  10.6  Measuring the severity of erythema nodosum leprosum – validation of the ENLIST ENL Severity Scale
            Stephen Walker

ILC1.3-034  10.7  A Prospective Randomized, Double-blind, Placebo Controlled Trial on the Effect of Extended Clofazimine on ENL in MB Leprosy
            Armi Maghanoy

ILC1.3-027  10.8  THALIDOMIDE IN TYPE II REACTIONS – LARGER EXPERIENCE OVER A DECADE
            Vivek Pai

Session 11.  History 1  Chair: Robertson

Monday 19th September 15.30 hours  Room 203ABCD

ILC2.1-013  11.1  Having a Conversation between The Humanities and The Sciences
            Jo Robertson

ILC2.1-006  11.2  The "discovery" of leprosy bacillus as a process: the history between science and society.
            Reinaldo Bechler

ILC2.1-003  11.3  The patient as historical agent in leprosy research – a vision from mid-twentieth century Uzuakoli, Nigeria
            John Manton

ILC2.1-007  11.4  Applying the “index of care” to a person who experienced leprosy in late Medieval England
            Charlotte Roberts

ILC2.1-010  11.5  New Evidence for an Old Debate: What do Bone Changes of Hands and Feet Reveal about the Palaeoepidemiology of Leprosy?
            Vitor MJ Matos

ILC2.1-011  11.6  Unusual prevalence of palatal perforations in the skeletons from the medieval leprosarium of St. Jorgen, Odense, Denmark
            Vitor Matos

ILC2.1-009  11.7  Assessing physiological stress in young people with leprosy buried at a Medieval English leprosarium using stable isotope analyses from high-resolution incremental dentine
            Kori Filipek

            11.8  History of Leprosy

Session 12.  Enabling enhanced participation  Chair: Soyagimi/Zhang Lianhua

Monday 19th September 15.30 hours  Room 203E
12.1 Enabling Enhanced Participation
Hiroe Soyagimi

12.2 Findings of the current situation of the participation by ILEP Temporary Expert Group – Michael Chen

12.3 Experience of the participation from different aspects - experience of the government - Case of CLAP in Philippines – Ernesto E. S. Villalon III

12.4 Experience of Self-help Group in Nepal – Hugh Cross

Session 13. Leprosy in the USA
Chair: White and Truman
Monday 19th September 15.30 hours
Room 305ABC

ILC2.3-054 13.1 Leprosy and Migration in the United States: Treatment Challenges for First-Generation Migrants and for Healthcare Professionals
Cassandra White, Judith Justice and Carlotta Hill

ILC4.4-014 13.2 Emerging zoonotic leprosy in the United States and pathological variants of Mycobacterium leprae
Richard Truman

ILC4.4-023 13.3 Molecular Detection of Mycobacterium leprae in Wild Armadillos and Increased Anti-PGL-I Titers in Individuals Consuming Them in Western Pará, Brazil.
John Spencer

Session 14. Stigma
Chair: PK Gopal
Monday 19th September 15.30 hours
Room 305DE

ILC2.3-033 14.1 "Concrete Actions to End Stigma and Discrimination" Gopal P.K.

ILC2.3-002 14.2 Stigma in leprosy: concepts, causes and determinants
Silatham Sermrittirong

ILC2.3-010 14.3 Assessment of Stigma As Perceived By the Persons Affected By Leprosy (PAL) from rural areas of Maharashtra State (India) - A Comparative Study of PALs With and Without Visible Disability.
Ashutosh Prabhavalkar

ILC2.3-012 14.4 Developing An Effective Social Multi-Drug Therapy To Counteract Leprosy Stigma: Urgent Need of The Hour
Sundar Rao

ILC2.3-022 14.5 Cultural validation of a new leprosy-related stigma measurement: SARI Stigma Scale
Dadun Dadun

ILC2.3-059 14.6 Stigma against leprosy and other NTDs – the case for joint approaches and action
Wim H van Brakel

ILC2.3-060 14.7 The SARI Project: how to measure leprosy-related stigma in the community
Wim H van Brakel

ILC2.2-018 14.8 The Impact of a Rights-Based Counselling Intervention To Reduce Stigma in People Affected by Leprosy in Indonesia
Mimi Lusli
Session 15. Surgery 1
Chair: Marcos Virmond
Monday 19th September 15.30 hours Room 307

ILC5.2-040 15.1 Factors influencing access to Leprosy related Reconstructive Surgery in India
Shyamala Anand

ILC5.2-023 15.2 Changes in plantar load following flap cover for plantar ulcers over the heel
and metatarsal heads
Jerry Joshua

ILC5.1-017 15.3 PATIENTS PERCEPTIONS ABOUT PAIN AND FUNCTIONAL LIMITATIONS
FOLLOWING PERIPHERAL NERVE DECOMPRESSION SURGERY IN LEPROSY
Maria Dias Torres Kenedi

ILC5.2-006 15.4 A New Approach to Lagophthalmos Surgery in Leprosy in Madhya Pradesh
state, India
Dr. Kamlakar Bhandarkar

ILC5.2-021 15.5 Partnership with NGOs/Government Leprosy Hospitals and Private
Orthopaedic Surgeons to Scale up to Sustain Reconstructive Surgery Services in India: Damien
Foundation Experience
Aashish Wagh

ILC5.2-053 15.6 Influence of the Insole (Platform for Tarsus) in the Body Balance Control of
the Leprosy Patient with Sensitivity Impairment
Marco Frade

ILC5.3-003 15.7 Functional Improvement and Factors Affecting Outcome after Opponens
Replacement in Patients with Median Paralysis due to Leprosy
Sourabha Mandal

ILC1.1-038 15.8 Combined Lasso and Opponensplasty: a single stage leprosy reconstructive
hand surgery that expedites recovery and reduces hospital stay by 6 weeks
Indra Napit

Session 16. Information systems & indicators for the global Strategy
Chair: Gillini
Monday 19th September 15.30 hours Room 308
Details waited

Session 50 Late Breaking Seminar: U-MDT
Chair Gerson Penna
Monday 19th September 15.30 hours Room 311
Speakers:
- Gerson Penna - Brazilian Clinical Trial – 25min
- Shen Jianping - Chinese Clinical Trial – 25min
- Axel Kroger - Indian Clinical Trial – 25min
- Ruth Butlin/K Alam - Bangladesh experience
- Paul Fine - Comments and discussion
Session 17. Post Exposure Prophylaxis 1  Chair: Fareed Mirza
Tuesday 20th September 13.30 hours  Room 201AB
ILC4.3-012  17.1 Emerging evidence from the Leprosy Post-Exposure Prophylaxis project: an overview.  Peter Steinmann
ILC4.3-014  17.2 An interim report on the operational feasibility of leprosy post-exposure prophylaxis in Dadra and Nagar Haveli, India  Anil Kumar
ILC4.3-022  17.3 Comparison of Implementation Aspects of Leprosy Post-Exposure Prophylaxis in India, Nepal and Indonesia  A Tiwari
ILC4.3-011  17.4 Negotiating and Implementing the Leprosy Post Exposure Prophylaxis Project in the Centralized Health Service of the Union of Myanmar.  Hugh Cross
ILC4.3-009  17.5 LPEP and Implementation Experiences From Nepal  Nandlal Banstola
ILC4.3-007  17.6 Modeling the long term impact of additional interventions on the new case detection rate of leprosy in three endemic countries and regions  David Blok

Session 18. Clinical Aspects  Chair: Sunil Dogra
Tuesday 20th September 13.30 hours  Room 201CD
ILC1.4-004  18.1 Histoid leprosy in post leprosy elimination era in India  Sunil Dogra
ILC1.3-030  18.2 Lepromatous leprosy with Lucio’s phenomenon report one case  Ziming Huang
ILC1.3-003  18.3 Retrospective Analysis of Persons Affected by Leprosy with Type 2 Reactions at Secondary Care Leprosy Referral Centre, South India  Kameswara Adiraju
ILC1.4-010  18.4 Clinical Profile and Trends of Childhood Leprosy over a Ten Year Period at a Tertiary Referral Centre  Sheela Daniel
ILC1.4-034  18.5 Biologics and leprosy – a systematic review  Eglantine Lebas
ILC1.5-003  18.6 Is corneal astigmatism an additional risk factor for vision handicap in leprosy patients?  Benjamin Nongrum

Session 19. History 2  Chair: Jinqquan Wang
Tuesday 20th September 13.30 hours  Room 203ABCD
ILC2.1-002  19.1 Brief Introduction to China’s Modern Leprosy Control Course (1840-1949)  Jinqquan Wang
ILC2.1-004  19.2 The Leper Home in Jerusalem 1867-2009  Ruth Wexler
ILC2.1-005  19.3 Patient Perspectives and Influences on Life in Uganda’s Colonial Leprosy Settlements, c. 1929-1962  Kathleen Vongsathorn
ILC2.1-008  19.4  Regaining a Place in History: The Identification of Individuals in Photographs Taken at Kalaupapa, Molokai, More than 100 Years Ago  Anwei Skinsnes Law

ILC2.1-012  19.5  Ending the Millennium lonely, from Isolated to the integration, promoting Transnational world heritage of Leprosy sites and spirit. Tse-Chun, Sawa Lai

Session 20.  Empowerment  Chair: Sunil Anand/Si Zhanjie

Tuesday 20th September 13.30 hours  Room 203E

ILC2.2-005  20.1  Life experiences of people with leprosy disability with diabetes  Dalwor Hossain

ILC2.2-006  20.2  Evidence on elimination of discrimination against persons affected by leprosy and their family members with reference to UN principles and guidelines in 6 rural districts of Maharashtra (India)  Ashutosh Prabhavalkar

ILC2.2-010  20.3  TAKE PART, TAKE THE LEAD – Rights-based Approach to Social Inclusion and Participation  Jacob Oommen

ILC2.2-014  20.4  Addressing Discriminatory Legislation in India - Initiatives and Experiences  Sunil Anand Dara

ILC2.2-019  20.5  ANTI LEPROSY LEGISLATIONS IN INDIA: BUREAUCRATIC CHALLENGES WITHIN THE INDIAN LEGAL FRAMEWORK  Sarah Nikita Renick

ILC2.2-020  20.6  EMPOWERMENT OF YOUTH FROM LEPROSY COLONIES AS CHANGE AGENTS  Chetna Verma

Session 21.  Co-infections and Infestations  Chair: Hagge

Tuesday 20th September 13.30 hours  Room 305ABC

ILC4.5-010  21.1  Are intestinal worms relevant to leprosy clinical care and outcomes: investigations of soil-transmitted helminth occurrence in Nepalese leprosy patients  Deanna A. Hagge

ILC4.5-008  21.2  Profile of Tuberculosis in patients attending a Leprosy hospital in Rural India  Joydeepa Darlong

ILC5.2-031  21.3  The importance of water, sanitation and hygiene (WASH) for lymphatic filariasis (LF) and leprosy care and inclusion  James Pender

ILC4.5-013  21.4  Combined Health Campaign: a successful strategy to face Leprosy, Trachoma and Soil-transmitted helminths (STHs)  Larissa Lopes Silva Scholte

ILC4.5-011  21.5  Tuberculosis Co-infection in Leprosy Patients: A decade of retrospective study in Anandaban Hospital of Nepal  Mahesh Shah Shudi

Session 22.  Social Aspects 2  Chair: Aprue Mong
**Tuesday 20th September 13.30 hours**  
**Room 305DE**

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion to Inclusion- Community Led Actions Reduce Leprosy Stigma and Prevent Isolation, Bogra District, Bangladesh</td>
<td>Aprue Mong</td>
</tr>
<tr>
<td>COMPARATIVE IMPACT OF INSTITUTIONAL AND COMMUNITY BASED INTERVENTIONS AGAINST DEFAULTING FROM MDT</td>
<td>RAJU M S</td>
</tr>
<tr>
<td>Estimation, Evaluation and Elimination of the 4Ds in Leprosy</td>
<td>Raju M S</td>
</tr>
<tr>
<td>Rural based Information Centre for Accessibility of Rights and Entitlements for persons affected by leprosy and other disabilities.</td>
<td>Bino Shadrach Berry</td>
</tr>
<tr>
<td>Leveraging the Influential Power of Religious Institutions to Reduce Leprosy-related Stigma in Local Communities</td>
<td>Praveen Gomez</td>
</tr>
<tr>
<td>Use of a cooperative model of community base rehabilitation to bring social status improvement for leprosy affected and general disabled in Nepal: a 5 year Prospective Study</td>
<td>Bishu Dhungana</td>
</tr>
</tbody>
</table>

**Session 23.  Insensitive Feet**  
**Chair: Larissa de Viveiro**

**Tuesday 20th September 13.30 hours**  
**Room 307**

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Association of Sensitivity Feet and Need for Use the Visual System in Postural Control in Individuals with Leprosy</td>
<td>Larissa Alamino Pereira de Viveiro</td>
</tr>
<tr>
<td>The Effectiveness of Mobile Prosthesis Services</td>
<td>Michael Zhiqiang Chen</td>
</tr>
<tr>
<td>Comparison of in-Shoe Plantar Pressure using MCR and Market Footwear</td>
<td>Bob Bowers</td>
</tr>
<tr>
<td>“Study of satisfaction level of patients with Protective footwear in Bihar and Jharkhan, India”</td>
<td>Rajni Kant Singh</td>
</tr>
<tr>
<td>Follow-up Study on Effectiveness of Customized Footwear: Implications for Involving General Healthcare Staff</td>
<td>Vivek Lal</td>
</tr>
<tr>
<td>Restoring the Mobility of Forgotten People with Mobile Foot Care Unit intervention in Bihar, India</td>
<td>Rajnikant Singh</td>
</tr>
</tbody>
</table>

**Session 24.  Epidemiology**  
**Chair: Vera Andrade**

**Tuesday 20th September 13.30 hours**  
**Room 308**

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison of trends in overall and grade 2 disability among new cases detection rates of leprosy by geographical regions. Brazil 2008-2014</td>
<td>Vera Lucia Gomes de Andrade</td>
</tr>
<tr>
<td>Multibacillary leprosy and male sex: a behavioral question?</td>
<td>Mauricio Lisboa Nobre</td>
</tr>
</tbody>
</table>
Fifty years of leprosy in Brazil: Joinpoint trend analysis from 1965 to 2014
Rosa Castália Franca Ribeiro Soares

Trends in the historical sequence of detection rates overall and in children less than 15 years of age Brazil from 1995 to 2014
Vera Lucia Gomes de Andrade

Diet-Related Risk Factors for Leprosy: A Case-Control Study
Inge Wagenaar

Knowledge, attitude and practice related to leprosy in Zinder, Republic of Niger
Yohanna Abdou

Session 25. Post Exposure Prophylaxis 2
Chair: Rosa Castália
Tuesday 20th September 15.30 hours Room 201AB

Operationalizing Pilot Project Post-exposure prophylaxis with immune and chemoprophylaxis for leprosy contacts: PEP-hans Brazil
Rosa Castália França Ribeiro Soares

Development and implementation of a health information management system for leprosy post exposure prophylaxis: challenges and issues
Millawage Supun Dilara Wijesinghe

The preventive effect of rifampicin as chemoprophylaxis on the incidence of leprosy remains evident after nearly 10 years of active follow-up.
Mirjam I. Bakker

Single-dose Rifampicin Chemoprophylaxis for leprosy contacts in Morocco
Ibtissam Khoudri

DELIVERING LEPROSY POST-EXPOSURE PROPHYLAXIS IN A REMOTE AREA: A Case of Lingat Village, Maluku, Indonesia
Steaven Dandel

Acceptability of a Rapid Diagnostic Test (RDT) for Leprosy Among Patients, House Contacts and Community Contacts in Cebu, Philippines
Florenda Roferos

DISTRIBUTION OF LEPROSY POST-EXPOSURE PROPHYLAXIS THROUGH EXTENDED CONTACT-TRACING WITH SELF-ScreenING APPROACH IN SUMENEP DISTRICT, INDONESIA.
Steaven Dandel

Session 26. Reactions
Chair: Erik Post/Diana Lockwood
Tuesday 20th September 15.30 hours Room 201CD

TENLEP: Treatment of Early Neuropathy in Leprosy: two multi-centre triple blind randomised placebo controlled clinical trials
Erik Post

Cortico-steroid adverse events in a large prospective randomized controlled clinical trial: Comparing 20 versus 32 weeks in the treatment of leprosy reaction/neuropathy
JW Brandsma
ILC1.3-021 26.3 Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: results of the randomized controlled TENLEP trial  Inge Wagenaar

ILC5.1-018 26.4 The Proportion of Sensory Nerves Improvement Detected by Monofilament: Prednisolone 32 weeks vs 20 weeks in Early Neuropathy of Leprosy Patient (Randomised Controlled Trial) in Surabaya & Madura. IndLinda Astari

ILC1.3-002 26.5 Recent Trends in Leprosy Reactions - the Chittagong Experience Mohammad RafiqulMowla

ILC1.3-006 26.6 The Inverse Relationship of Pro-and Anti-inflammatory Lipid Mediators in Leprosy Patients with Type 1 Reaction J.T. Belisle

ILC1.3-015 26.7 Nerve ultrasound as an additional diagnostic and prognostic tool to monitor leprosy reactions in a two year follow up study MeherVaniChaduvula

ILC3.1-017 26.8 TGF-β showed Synergy Effect with IL-6 in Leprosy Reactions to produce Th17 Cells. Chaman Saini

Session 27. Disability Management Chair: VV Pai

Tuesday 20th September 15.30 hours Room 203ABCD

ILC5.2-032 27.1 UTILITY OF DISABILITY CARE SERVICES - BENEFITS AND ITS IMPACT – FIELD OBSERVATIONS IN URBAN SLUMS OF MUMBAI VivekPai

ILC5.1-013 27.2 Association of the Degree of Physical Disability and Need for Use of Visual and Somatosensory Information for Postural Control of Individuals with Leprosy Larissa Alamino Pereira de Viveiro

ILC4.2-013 27.3 Evaluation of FAIRMED’s (FM) pilot POID project in India John Kurian George

ILC5.2-035 27.4 Need of community based disability management program in the post integration era. Bino Shadrach Berry

ILC5.2-043 27.5 Strengthening Disability Care in General Health Care System Through Referral Centres in Odisha (India) Dr Surendranathpati

ILC5.3-006 27.6 Crossing Barriers: Disability and Dependence to Capability and Self Reliance by a Group of Leprosy Affected. PIUS KALATHIL

ILC5.3-033 27.6 Are Persons Affected by Leprosy resident in Leprosy settlements willing to be reintegrated into their local communities? Linda Ugwu

ILC5.3-039 27.8 Analysis of the social support condition and its influence factors among people affected by leprosy in WenZhou district of Zhejiang Province Xiang-yan CHEN

Session 28. Workshop: defining early leprosy Chair: Scollard/Salgado

Tuesday 20th September 15.30 hours Room 203E
Details awaited

Session 29.  Neglected Tropical Diseases  Chair: Mirian Eddyani

Tuesday 20th September 15.30 hours  Room 305ABC

ILC4.5-005  29.1  The accuracy of the clinical and microbiological diagnosis of Buruli ulcer  Miriam Eddyani

ILC4.5-003  29.2  Elimination of Lymphatic filariasis (NTD) .... Dream or Reality - An evaluation of Mass Drugs Administration (MDA) 2015 in Bihar, India.  Rajni Kant Singh

ILC4.2-010  29.3  Leprosy and Buruli Ulcer Control in Nigeria: Taking Stock and Planning for Impact  Ochuko Urhioke

ILC4.5-006  29.4  Integrated Strategy for Case Management of five Neglected Tropical Diseases (Buruli ulcer, Human African Trypanosomiasis, Leishmaniasis, Leprosy and Yaws) in the WHO African Region.  Alexandre TIENDREBEOGO

ILC4.5-007  29.5  School-based survey for neglected tropical diseases presenting skin symptoms (skin NTDs) in Cote d’Ivoire: project implementation and preliminary results  Rie Roselyne Yotsu

ILC5.2-009  29.6  Integrated Prevention of Disability Programme for persons with disabilities due to leprosy and Elephantiasis In Bihar, India  Amar Singh

ILC5.2-029  29.7  Sustainable Inclusive Self-care by Persons Disabled due to Leprosy, Lymphatic Filariasis (LF) and Diabetes  Mohammad A. Arif

ILC5.3-043  29.8  The NTD Morbidity and Disability (NMD) Toolkit Project: selection of tools and preliminary validation in Fortaleza, Brazil  Wim H van Brakel

Session 30.  Molecular research  Chair: U Gupta/M Moraes

Tuesday 20th September 15.30 hours  Room 305DE

First Part Chair: U Gupta

ILC3.3-001  30.1  Molecular biology and genetics in leprosy  Umesh Gupta

ILC3.3-002  30.2  Fine-mapping and functional annotation analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cirrhosis, Crohn’s disease and leprosy  Yonghu Sun

ILC3.3-029  30.3  Acetylation and hydroxylation phenotypes in populations of five geographical regions of Brazil based on the genome: possible influence of pharmacogenetics in the therapeutic management of leprosy  AR Santos

ILC3.3-009  30.4  Molecular Typing of Mycobacterium leprae Among Multi-Case Families and Multi-Case Villages in Cebu, Philippines  Marivic Balagon

Second Part Chair: Moraes

ILC3.3-033  30.5  From the genetic association studies to host-directed therapies in leprosy  Milton Ozório Moraes
ILC3.3-017  30.6  Novel Genetic Markers Associated with Leprosy Susceptibility in a Group of Incident Household Contacts from Brazil  Lucia Elena Alvarado-Arnez

ILC3.3-034  30.7  Whole genome sequencing of leprosy bacilli: from efficient DNA extraction methods to analysis of 100+ genomes  Charlotte Avanzi

ILC3.3-010  30.8  Medieval leprosy genomes: Retracing the evolutionary history of Mycobacterium leprae using ancient DNA  Verena J. Schuenemann

Session 31.  Surgery 2  Chair: Zhang Guocheng

Tuesday 20th September 15.30 hours  Room 307

ILC5.3-005  31.1  Evaluation of Long-term Effect of Tibialis Posterior Transfer for the Correction of Foot-drop in Leprosy  Farha Sultana

ILC5.3-013  31.2  A MODIFICATION OF THE SURGICAL PROCEDURE TO PREVENT POST-OPERATIVE SUBLIMIS MINUS DEFORMITY AT THE DONOR FINGER – A LONG TERM FOLLOW-UP  Ananth Reddy. Dr.Sreepuram

ILC5.3-018  31.3  FUNCTIONAL INDEPENDENCE AFTER TENDON TRANSFER SURGERY IN LEPROSY  K Ilavarasi

ILC5.3-025  31.4  The Outcome of Lasso Surgery for Claw Hand Correction in Female Leprosy Patients  Nabeela Khanam

ILC5.3-030  31.5  Use of a simple Qualitative Participatory Tool to assess the Impact of Reconstructive Surgery in Leprosy  Shyamala Anand

ILC5.3-031  31.6  PREVENTION OF POST-OPERATIVE SUBLIMIS MINUS DEFORMITY BY MODIFIED SURGICAL PROCEDURE AT DONOR FINGER – A LONG TERM FOLLOW UP  ANANTH REDDY SREEPURAM

ILC5.3-032  31.7  Long-term effect of treatment using modified temporalis muscle transfer for correcting lagophthalmos in leprosy  Liangbin Yan

ILC5.3-044  31.8  An alternative method, gastrocnemius recession, for increasing plantar flexion outcomes in Posterior Tibial Tendon Transfer for Foot Drop Correction  Pradip Sapkota

Session 32.  Case Detection  Chair: Ousmane Faye

Tuesday 20th September 15.30 hours  Room 308

ILC4.2-043  32.1  Improvement of leprosy detection through a one-day basic dermatology training of Primary health care workers in Mali  Ousmane Faye

ILC4.2-041  32.2  Role of grassroots level health care workers in leprosy programme with particular reference to Accredited Social Health Activists (ASHA) in India  Vijaya Krishnan Nair

ILC4.2-039  32.3  Factors responsible for delay in reporting for leprosy diagnosis and treatment  Wim Brandsma
Role of Community Health Volunteers in promoting early diagnosis in Leprosy Care: Findings from a multi-centric study in India  Thirumugam Muthuvel

Early detection and sustainable leprosy care: an approach through community participation  Bino Shadrach Berry

IMPROVING LEPROSY CASE DETECTION THROUGH LEPROSY FRIENDLY VILLAGES  Teky Budiawan

Study on the awareness status of key message on leprosy control among publics in Zhejiang   Guo-cheng Zhang

Acceptability And Benefit Of Annual Contact Examinations Beyond The Standard 2 Or 5 Year Practice  C Ruth Butlin

Session 33.  Drug Resistance 2  Chair: Mannam Ebenezer

Wednesday 21st September 08.30 hours  Room 201AB

Evaluation of Bactericidal Activity of New Drugs and Drug Combinations in Mice Infected With Rifampicin Resistant Mycobacterium leprae  Priya Joseph

Analysis of 124 Leprosy Relapse Cases after MDT in China  Peiwen Sun

Leprosy Drug Resistance Monitoring in Nepal  Deanna A. Hagge

Evaluation of new Antibacterial Drug Combinations in Murine Model of leprosy to identify short duration alternative to Standard WHO regimen of Multibacillary – Multidrug Therapy  Madhusmita Das

Detection of Mycobacterium leprae drug resistance mutations from leprosy patients from India by using molecular methods.  U Sengupta

Session 34.  Immunology 1  Chair: Kathryn Dupnik

Wednesday 21st September 08.30 hours  Room 201CD

Transcriptome Profiles of Peripheral Blood Mononuclear Cells in Leprosy Prior to and at the Time of RR and ENL  Kathryn Dupnik

A Systematic Review of the Immunology of Erythema Nodosum Leprosum  Anastasia Polycarpou

A hospital based retrospective study of the morbidity and mortality associated with Erythema Nodosum Leprosum at the Oswaldo Cruz Foundation, Rio de Janeiro  Stephen Walker

Patterns of Cytokine Expression in the Blood and Skin biopsy Samples from Patients with Erythema Nodosum Leprosum: The influence of Prednisolone Treatment  Edessa Negera Gobena

A Case-control Study Investigating T-cell Regulation in Erythema Nodosum Leprosum  Edessa Negera Gobena
ILC3.1-007 34.6  Does Mycobacterium Leprae signal through Toll-like Receptor-4?
Anastasia Polycarpou

Session 35. Self Care  Chair: Li-mei Wu
Wednesday 21st September 08.30 hours  Room 203ABCD
ILC5.3-037 35.1 Evaluation of the effect of Leprosy patients “Self Care Group” (SCG) Li-mei Wu
ILC5.2-051 35.2 Impact of Self-care groups of persons affected by leprosy on clinical and social parameters, a comparative cohort study in India, Indonesia and Nepal Erik Post
ILC2.4-021 35.3 Can Leprosy Self-Care Groups Contribute to Efforts to Secure Leprosy Control? Hugh Cross
ILC2.4-017 35.4 “Footwear Mela” – A new initiative by LEPTA Society” Rajni Kant Singh
ILC2.4-009 35.5 Self-help group: a socio-economic rehabilitation approach to regain human dignity and reduce leprosy-related stigma in the Northeastern community, Thailand Art Donwichai

Session 36. Participation  Chair: Beatriz Miranda/Liu Yangying
Wednesday 21st September 08.30 hours  Room 203E
ILC2.3-052 36.1 The walls of this hospital did not take my life: Elderly people living in a hospital for people affected by Hansen’s Disease in Ecuador Beatriz Miranda
ILC2.4-003 36.2 My eventful journey to enhance Integration, Dignity and Economic Advancement Sangkwon Jung
ILC2.4-016 36.3 Transformation from service receiver to advocator —the role of the participation of people affected by leprosy in leprosy service Michael Zhiqiang Chen
ILC2.4-024 36.4 “Increased social acceptance and dignity of leprosy disabled after Adult literacy” Dalwor Hossain
ILC2.4-029 36.5 Reuniting People With Their Families and Communities To Increase Participation in Society Jackson Nyarko
ILC2.4-030 36.6 Improving inclusion and participation of people affected by leprosy and other disabilities by providing a barrier free environment Dhondge Suresh

Session 37. Surveys 1  Chair: Patricia Rosa
Wednesday 21st September 08.30 hours  Room 305ABC
ILC4.4-026 37.1 Active search of leprosy cases among school children with positive serology using a rapid test in an endemic area of Brazil Patriciasammarco ROSA
Childhood Leprosy through the Post-Leprosy Elimination Era: a retrospective analysis of Factors which influence late reporting-children-Grade-II disability for RCS—an Assessment of Respon Factors

Ananth Reddy Sreepuram

The trends child cases reported to The Leprosy Mission Hospital Nandnagri Delhi-93 in last 5 years (2011-2015)

Saurabh Mishra

28

GonalvesBarretoJosafá

PROFILE OF NASAL SWAB PCR AND SEROPOSITIVITY LEVEL OF ANTIBODY RESPONSE TO M.leprae PGL-1 AMONG SCHOOL CHILDREN IN THE NORTH AND SOUTH COASTAL REGION OF EAST JAVA PROVINCE IN INDONESIA

Dinar Adriaty

Relevance of various methods used in early detection of leprosy

Tina Mendis

ILC5.2-012  37.2  Childhood Leprosy through the Post-Leprosy Elimination Era: a retrospective analysis of Factors which influence late reporting-children-Grade-II disability for RCS—an Assessment of Respon Factors  Ananth Reddy Sreepuram

ILC4.2-054  37.3  The trends child cases reported to The Leprosy Mission Hospital Nandnagri Delhi-93 in last 5 years (2011-2015)  Saurabh Mishra

ILC4.2-008  37.4  28  GonalvesBarretoJosafá

ILC4.1-038  37.5  PROFILE OF NASAL SWAB PCR AND SEROPOSITIVITY LEVEL OF ANTIBODY RESPONSE TO M.leprae PGL-1 AMONG SCHOOL CHILDREN IN THE NORTH AND SOUTH COASTAL REGION OF EAST JAVA PROVINCE IN INDONESIA  Dinar Adriaty

ILC2.3-046  37.6  Relevance of various methods used in early detection of leprosy  Tina Mendis

Session 38.  Disability and reaction research (LRI)  Chair: William Faber

Wednesday 21st September 08.30 hours  Room 305DE

ILC5.2-044  38.1  Disability and reactions  William R Faber

ILC1.3-023  38.2  Disability and Reactions Workshop: The Erythema Nodosum Leprosum International STudy Group -ENLIST  Stephen Walker

ILC1.3-032  38.3  Treatment of Early Neuropathy in Leprosy (TENLEP): outcomes of a randomised, double blind, placebo controlled clinical trial to treat subclinical neuropathy with prednisolone.  Erik Post

ILC5.2-012  38.4  Burden of treatment: An important factor in leprosy-related disability and reactions  Pim Kuipers

ILC5.3-048  38.5  Mind the gap – inclusive medical rehabilitation for persons with disability due to leprosy, lymphatic filariasis and diabetes mellitus in Indonesia  WidyaPrasetyanti

Session 39.  Rehabilitation  Chair: Bowers

Wednesday 21st September 08.30 hours  Room 307

ILC5.3-029  39.1  Attributable Impact of CBR Self-Help Groups to Enhance the Socio Economic Status of People Affected by Leprosy and Other Disabilities  Bob Bowers

ILC5.3-021  39.2  Impact of specially designed Vocational Training Programmes, for persons affected by leprosy on Students, their Families and Communities  Shyla Francis

ILC5.3-014  39.3  Inclusive Rehabilitation Approach in Leprosy - An Experience from Backward Districts in India  KanagasabapathyVaikundanathan

ILC5.3-011  39.4  Promoting Inclusive Development – a CBR Strategy in Tribal Location  Shibu V. George

ILC5.2-008  39.5  A Step ahead Towards Self Reliance - SewaDoot Scheme in Leprosy Colonies of Madhya Pradesh  Dr.BhandarkarKamlakar
The importance of water, sanitation and hygiene (WASH) for lymphatic filariasis (LF) and leprosy care and inclusion. James Pender

**Session 40. Biomarkers**  
**Chair: Geluk**  
**Wednesday 21st September 08.30 hours**  
**Room 308**

ILC3.1-011 40.1 WhatsLep? Monitoring multiple immune response markers in blood and urine AnnemiekGeeluk

ILC3.1-012 40.2 APPLICATION OF A FIELD-FRIENDLY LF ASSAY FOR IMMUNODIAGNOSIS OF LEPROSY IN A BCG INTERVENTION FIELD TRIAL IN BANGLADESH : PROTOCOLS AND RECOMMENDATIONS Anouk van Hooij

ILC4.4-008 40.3 THE USE OF IFNγ AND CXCL10 BIOMARKERS FOR M. LEPRAE-SPECIFIC CELL MEDIATED IMMUNITY BY WHOLE BLOOD ASSAY IN HIGHLY ENDEMIC AREAS IN BRAZIL Malcolm S. Duthie

ILC4.4-024 40.4 The Use of RLEP Amplification and Anti-PGL-I Titer to Evaluate Leprosy Infection Rates in Families Living in Hyperendemic Cities in Pará, Brazil John Spencer

ILC3.1-016 40.5 Search for bio-markers of Mycobacterium leprae infection Yumi MAEDA

ILC3.1-027 40.6 Heme Oxygenase 1 as a marker of infection in leprosy household contacts Roberta OlmoPinheiro

**Session 41. Chemotherapy**  
**Chair: Narasimha Rao/Gerson Penna**  
**Wednesday 21st September 10.30 hours**  
**Room 201AB**

ILC1.2-005 41.1 RE-EXAMINING THE EVIDENCE ON UNIFORM MDT (UMDT) FOR LEPROSY Narasimha Rao P

ILC1.2-013 41.2 MOXIFLOXACIN BASED REGIMENS IN LEPROSY – CLINICAL OBSERVATIONS ON OCCURRENCE OF REACTIONS AND BACTERIAL DECLINE VivekPai

ILC1.2-001 41.3 Late Disability Outcomes in MB Leprosy Cases Treated With Only 6m MBMDT C. Ruth Butlin

ILC1.4-036 41.4 Human Leukocyte Antigenisassociatedwith hypersensitivity reaction induced by dapsone in Brazilian leprosy patients DejairCaitano do Nascimento

ILC1.2-027 41.5 Morbidity and Mortality Associated With Dapsone Hypersensitivity: A Retrospective Hospital Based Study SuwashBaral

ILC1.3-029 41.6 Analysis of clinical characteristics of thirty-three leprous reactions and evaluation of therapeutic effect of prednisone on leprosy cases after combined chemotherapy Senmiao Zhang

**Session 42. Immunology 2**  
**Chair: Gigi Ebenezer**
Wednesday 21st September 10.30 hours  Room 201CD

ILC3.3-028  42.1  Richard Truman
ILC4.3-002  42.2  Safe and Effective Post-Exposure Prophylaxis With The LEP-F1/GLA-SE, but not BCG, Vaccine In M. leprae-infected Armadillos.  Malcolm S. Duthie
ILC3.1-013  42.3  Post-exposure Vaccination of M.leprae–Infected Armadillos does not Exacerbate Peripheral and Cutaneous Nerve Involvement  Gigi Ebenezer
ILC3.1-038  42.4  Studies on immuno-epidemiology of leprosy by using PGL-1-ELISA of blood from earlobes: A comprehensive report  QinXue Wu
ILC3.1-022  42.5  Vitamin D Mediated Immune Modulation in Leprosy  Venkata Sanjeev Kumar Neela

Session 43.  French Session 2  Chair: C Roch Johnson

Wednesday 21st September 10.30 hours  Room 203ABCD

ILC4.2-050  43.1  Expérience de l’enquêteautour des cas de lèpre multi bacillaire au Bénin: Résultats et le?ons apprises  Didier Agossadou
ILC4.2-051  43.2  La lèpre au Cameroun quinzeannées après l’éliminationentant que problème de santé publique.  Earnest NJIH TABAH
ILC5.2-027  43.3  place actuelle de la chirurgiedans la lèpre  Francis Chaise
ILC5.2-030  43.4  La Prévention des Invalidités et la Réadaptation Physique des malades de la lèpre :L’expérienceenAfrique Francophone  MICHEL YVES GRAUWIN

Session 44.  Quality of Life  Chair: Maria Lambert/Wang Xiaohua

Wednesday 21st September 10.30 hours  Room 203E

ILC2.3-034  44.1  Health Related Quality of Life (HRQoL) in patients with leprosy reactions, at ALERT, in Ethiopia - an ENLIST Group study  Maria Saba Lambert
ILC2.3-029  44.2  A Study To Identify Social Determinants Contributing To The Delayed Treatment Seeking Among New Leprosy Cases In 6 Districts Of Maharashtra State (India).  AshutoshPrabhavalkar
ILC2.3-023  44.3  The Impact of Erythema Nodosum Leprosum and Nerve Function Impairment on Health Related Quality of Life in Purulia, West Bengal, India – an ENLIST Group study  JoydeepaDarlong
ILC2.3-015  44.4  Reduction of Grade 2 disabilities among untreated child leprosy cases to zero - challenges and steps needed based on a critical analyses of late registrations seen at a Leprosy Referral Centre in We  JoydeepaDarlong
ILC2.3-013  44.5  The Impact of Erythema Nodosum Leprosum on Health Related Quality of Life in Cebu, Philippines – an ENLIST Group Study  ArmiMaghanoy
ILC2.3-011  44.6  Disability Profile and Gender Issues in Female Leprosy Patients at Diagnosis in a Referral Hospital in Northern India  Farha Sultana

Session 45.  Surveys 2  Chair: Annamma John

Wednesday 21st September 10.30 hours  Room 305ABC

ILC2.3-031  45.1  Assessment of Leprosy awareness, knowledge and attitudes in the community across 3 endemic states in India  Annamma John

ILC4.1-055  45.2  Unexpectedly High Leprosy Seroprevalence Detected Using a Random Surveillance Strategy in Midwestern Brazil: A Comparison of ELISA and a Rapid Diagnostic Test  Marco Frade

ILC4.2-029  45.3  The Survey on Self-examination Behavior among Leprosy’s contact at high risk area in Thailand.  ManitChaninporn

ILC4.2-030  45.4  Analysis on Value of Active Survey in Case Detection of Leprosy at Five Major States in India  Srinivas Govindarajulu

ILC4.2-040  45.5  A STUDY OF NEW LEPROSY CASE FINDING BY ACTIVE SEARCH IN DERMATOLOGICAL DISEASE PATIENT (ADP) DATABASE IN KANTARALUK HOSPITAL, SISAKET  jiramahasapany

ILC4.2-113  45.6  The survey of the current situation of prevention and treatment of Hunan talents in leprosy control field  Yanfei KUANG

Session 46.  Inclusion Research (LRI)  Chair: van Brakel

Wednesday 21st September 10.30 hours  Room 305DE

ILC2.4-035  46.1  Leave no one behind – key aspects of inclusion research  Wim van Brakel

ILC2.4-038  46.2  Inclusion research from a disabled person’s perspective  Mimi Lusli

ILC2.4-036  46.3  "If you talk the talk, you’ve got to walk the walk": reflections from the SARI project on inclusive research.  Ruth Peters

ILC2.4-037  46.4  The BRIDGES project – CBR and sustainability  SilathamSermrittirong

Session 47.  Early Diagnostics and Transmission  Chair: Ann Aerts

Wednesday 21st September 10.30 hours  Room 307

47.1  Criteria for a developing a PCR test  Fareed Mirza

ILC4.4-012  47.2  The minimum requirements of a leprosy diagnostic test for subclinical cases to reduce leprosy transmission: a modelling study  David Blok

ILC4.4-025  47.3  Identification of early diagnostic biomarkers of leprosy  Youhua Yuan
ILC3.2-005  40.4  Evaluation of the Diagnostic Potential of Auramine O staining for the diagnosis of Leprosy.  Abraham Aseffa

ILC5.2-037  47.5  DIAGNOSTIC TEST OF Krox-20, PMP22, PROTEIN 0, NGF, AND NRG1 EXAMINATION TO DETECT EARLY DISABILITY IN LEPROSY  Dhelya Widasmara

ILC4.4-003  47.6  A Double-Blind Evaluation on the Concordance Rate (Sensitivity) of a Lateral Flow-Based Rapid Immunodiagnostic Test with Clinical, Bacteriologic and Histopathologic Findings among New Leprosy Patients  Malcolm S. Duthie

Session 48.  Morbidity assessment  Chair: Yu Meiwen/Xiang-yan Chen

Wednesday 21st September 10.30 hours  Room 308

ILC5.3-040  48.1  Evaluation and analysis of anxiety and depression and their related factors in people affected by leprosy  Xiang-yan CHEN

ILC5.1-005  48.2  The Prevalence Of Neuropathic Pain And Its Impact On The Functional Capacity And Psychological Wellbeing Of Leprosy Patients In Indonesia  Norana Abdul Rahman

ILC5.1-009  48.3  Comparison of Eye Hand Feet (EHF) Scores at the time of Leprosy Diagnosis and Release From Therapy (RFT)  Jaganath Maharjan

ILC5.2-020  48.4  Disability Status of Leprosy Patients at Diagnosis in an Endemic Area of Nigeria: Trends and Determinants  Joseph N Chukwu

ILC5.3-022  48.5  P-Scale and SALSA Scale to Determine Baseline Values of Restriction In Participation And Activity Among Patients With Food Drop Due To Leprosy  Sourabha Mandal